{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:57:56Z","timestamp":1790542676951,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.heliyon.2024.e32432","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T10:17:14Z","timestamp":1717582634000},"page":"e32432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatment"],"prefix":"10.1016","volume":"10","author":[{"given":"Tero","family":"Ylisaukko-oja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3406-8612","authenticated-orcid":false,"given":"Clas-G\u00f6ran","family":"af Bj\u00f6rkesten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Eberl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Nuutinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airi","family":"Jussila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauliina","family":"Molander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritva","family":"Koskela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Blomster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku","family":"Pajala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuire","family":"Ilus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Haiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4011-564X","authenticated-orcid":false,"given":"Bianca","family":"Kovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saija","family":"Silvola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4629-0560","authenticated-orcid":false,"given":"Jari","family":"Jokelainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8069-5273","authenticated-orcid":false,"given":"Taina","family":"Sipponen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e32432_bib1","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e32432_bib2","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/ibd\/izx100","article-title":"Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-Part I","volume":"24","author":"Knowles","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.heliyon.2024.e32432_bib3","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e32432_bib4","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An overview of the mechanism of action of the monoclonal antibody vedolizumab","volume":"10","author":"Wyant","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.heliyon.2024.e32432_bib5","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","article-title":"Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease","volume":"53","author":"Schreiber","year":"2018","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.heliyon.2024.e32432_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ecco-jcc\/jjx143","article-title":"Vedolizumab in IBD-lessons from real-world experience; A systematic review and pooled analysis","volume":"12","author":"Engel","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.heliyon.2024.e32432_bib7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e32432_bib8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e32432_bib9","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.heliyon.2024.e32432_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","article-title":"Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn's disease: results from the VISIBLE 2 randomised trial","volume":"16","author":"Vermeire","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.heliyon.2024.e32432_bib11","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.heliyon.2024.e32432_bib12","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e32432_bib13","first-page":"130","article-title":"Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases","volume":"17","author":"Feagan","year":"2019","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.heliyon.2024.e32432_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease in patients na\u00efve to or who have failed tumor necrosis factor antagonist therapy","volume":"23","author":"Sands","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.heliyon.2024.e32432_bib15","first-page":"1168","article-title":"Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis","volume":"54","author":"Attauabi","year":"2022","journal-title":"Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver"},{"key":"10.1016\/j.heliyon.2024.e32432_bib16","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/gast.2002.31072","article-title":"A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease","volume":"122","author":"Sandborn","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.heliyon.2024.e32432_bib17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis","volume":"132","author":"D'Haens","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.heliyon.2024.e32432_bib18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest. Endosc."},{"key":"10.1016\/j.heliyon.2024.e32432_bib19","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e32432_bib20","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/ecco-jcc\/jjz162","article-title":"Therapeutic drug monitoring of biologics during induction to prevent primary non-response","volume":"14","author":"Sparrow","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.heliyon.2024.e32432_bib21","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1080\/00365521.2021.1938206","article-title":"Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting","volume":"56","author":"Kolehmainen","year":"2021","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.heliyon.2024.e32432_bib22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/00365521.2017.1416160","article-title":"High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)","volume":"53","author":"Ylisaukko-Oja","year":"2018","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.heliyon.2024.e32432_bib23","article-title":"Increasing incidence of inflammatory bowel disease with greatest change among the elderly: a nationwide study in Finland, 2000-2020","author":"Kontola","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.heliyon.2024.e32432_bib24","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1177\/2050640620948802","article-title":"Effectiveness and safety of vedolizumab in biologically na\u00efve patients: a real-world multi-centre study","volume":"8","author":"Macaluso","year":"2020","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.heliyon.2024.e32432_bib25","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s00384-021-03943-5","article-title":"Profile of patients with inflammatory bowel disease in conjunction with unmet needs and decision-making for choosing a new biologic therapy: a baseline analysis of the VEDOIBD-Study","volume":"36","author":"di Giuseppe","year":"2021","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.heliyon.2024.e32432_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221080793","volume":"15","author":"Pudipeddi","year":"2022","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.heliyon.2024.e32432_bib27","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumour necrosis factor \u03b1 real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: results from the EVOLVE study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.heliyon.2024.e32432_bib28","doi-asserted-by":"crossref","unstructured":"Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Efken P, Mohl W, Krause T, et al. Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-na\u00efve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDOIBD-study. Aliment. Pharmacol. Ther. n.d.;n\/a. https:\/\/doi.org\/10.1111\/apt.17616.","DOI":"10.1111\/apt.17616"},{"key":"10.1016\/j.heliyon.2024.e32432_bib29","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41598-023-28907-3","article-title":"Vedolizumab is superior to infliximab in biologic na\u00efve patients with ulcerative colitis","volume":"13","author":"Sablich","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e32432_bib30","doi-asserted-by":"crossref","first-page":"i714","DOI":"10.1093\/ecco-jcc\/jjac190.0716","article-title":"P586 vedolizumab in mild to moderate Crohn's disease patients na\u00efve to biological therapy: a multicentric observational study","volume":"17","author":"Dotti","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.heliyon.2024.e32432_bib31","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12876-020-01332-w","article-title":"Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review","volume":"20","author":"Helwig","year":"2020","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.heliyon.2024.e32432_bib32","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/ibd\/izab257","article-title":"Translating results from VARSITY to real world: adalimumab vs vedolizumab as first-line biological in moderate to severe IBD","volume":"28","author":"Moens","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.heliyon.2024.e32432_bib33","series-title":"Eur Med Agency","year":"2018"},{"key":"10.1016\/j.heliyon.2024.e32432_bib34","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/apt.15484","article-title":"Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases","volume":"50","author":"Singh","year":"2019","journal-title":"Aliment. Pharmacol. Ther."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024084639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024084639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:47:52Z","timestamp":1790542072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024084639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2405844024084639"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e32432","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatment","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e32432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e32432"}}